AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Truist Financial analyst assigns Buy rating to Caribou Biosciences with $3.50 price target.
ByAinvest
Friday, Aug 15, 2025 12:33 pm ET1min read
Caribou Biosciences (CRBU) received a Buy rating from Truist Financial analyst Asthika Goonewardene, with a price target of $3.50, representing a 75% upside from current levels. The company has a Moderate Buy analyst consensus and a one-year high of $3.00 and low of $0.66.
Caribou Biosciences, Inc. (CRBU) reported its second-quarter 2025 financial results, with the company's president and CEO, Rachel Haurwitz, PhD, highlighting the progress of its allogeneic CAR-T cell therapies, CB-010 and CB-011, in the treatment of large B cell lymphoma and multiple myeloma, respectively [1].The company's cash, cash equivalents, and marketable securities stood at $183.9 million as of June 30, 2025, down from $249.4 million at the end of 2024. Caribou expects this funding to support its current operating plan until the second half of 2027 [1].
Caribou's licensing and collaboration revenue decreased to $2.7 million for the three months ended June 30, 2025, from $3.5 million in the same period last year. Research and development expenses were $27.7 million, down from $35.5 million in the previous year, primarily due to strategic pipeline prioritization and related workforce reduction [1].
The company reported a net loss of $54.1 million, or $0.58 per share, basic and diluted, for the second quarter 2025, compared to $37.7 million, or $0.42 per share, in the same period last year. Non-GAAP net loss, excluding non-cash impairment charges, was $32.8 million, or $0.35 per share, basic and diluted [1].
Analysts have responded positively to Caribou Biosciences' progress. Truist Financial analyst Asthika Goonewardene has assigned a Buy rating to the company, with a price target of $3.50, representing a 75% upside from current levels. This rating is in line with the company's Moderate Buy analyst consensus [1].
References:
[1] https://www.nasdaq.com/press-release/caribou-biosciences-reports-second-quarter-2025-financial-results-and-provides
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet